Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Coya Therapeutics Inc.

By Ernest Dela Aglanu, Benzinga Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and commercialization of COYA 301 — the company’s low-dose IL-2 subcutaneous administration product candidate. For industry watchers, including investors, this might be very important, especially as multiple autoimmune diseases have largely unmet medical needs. A deep dive into the statistics by the American Autoimmune Related Diseases Association (AARDA) shows that an estimated ~50 million Americans have one or more autoimmune diseases. More worryingly, AARDA further said approximately 75% of those affected are women and tend to cluster in families, impacting multiple family members and generations. Autoimmune diseases are among the top 10 leading causes of death among American women. Expansion Of Its Exclusive Worldwide Rights The statistics around autoimmune diseases are certainly worrying. To help make a difference, players like Coya are actively ramping up and expanding their therapies to address the needs of the market. Coya just announced the expansion of their exclusive worldwide rights with ARScience Biotherapeutics Inc. for the development and commercialization of COYA 301, Coya’s low-dose IL-2 subcutaneous administration product candidate. Since 2020, the clinical-stage biotechnology company has been developing multiple therapeutic platforms to enhance T cell (Treg) function, including biologics and cell therapies. COYA 301 is an immunomodulatory cytokine for subcutaneous administration intended to enhance regulatory Treg function in vivo to treat the systemic and neuro-inflammation underlying certain autoimmune and neurodegenerative diseases. Under the expanded terms of the agreement with ARScience, Coya reports that it has been granted the rights to develop and commercialize COYA as a combination therapy across multiple therapeutic areas and disease conditions and as a monotherapy for various neurodegenerative disorders and autoimmune diseases. The company expatiated that these additional rights expand on the rights provided in the original license, which allowed Coya to develop and commercialize the product candidate as monotherapy for a number of neurodegenerative conditions and as a combination Treg-based therapy across multiple therapeutic areas. “We believe that Treg dysfunction is a common characteristic in certain neurodegenerative and autoimmune diseases. The expansion of the license agreement enables our development of COYA 301 in a potentially larger group of patients suffering from progressive diseases characterized by sustained inflammation,” Howard Berman, Ph.D., CEO of Coya, said in a statement. According to him, the company’s strategy is to develop COYA 301 as a monotherapy and in combination with other immunomodulatory drugs ( COYA 302 ) to potentially mitigate persistent inflammation. Carlos Banado, CEO of ARScience Biotherapeutics, also commenting on the licensing agreement, noted, “there is not currently an approved recombinant human low-dose IL-2 for therapeutic use. The development of a low-dose IL-2 formulation, delivered via a subcutaneous injection, may provide effective treatment in a wide range of diseases characterized by increased inflammation. We are confident that Coya Therapeutics has the expertise to develop and commercialize this asset in multiple indications, and we look forward to a successful collaboration.” The licensing agreement could be significant, especially as dysfunctional Tregs are the underlying cause behind numerous conditions, including neurodegenerative, metabolic and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in a lack of homeostasis of the immune system. Luckily, Coya says its investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. The company’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The expansion of exclusive worldwide licensing agreement could give Coya an edge while having a positive impact on the global autoimmune disease diagnostics market with players like Exagen Inc. (NASDAQ: XGN), Oncimmune Holdings PLC (LON: ONC), and Retromer Therapeutics. With the global market estimated to be worth $4.7 billion in 2021 and expected to reach about $8 billion by 2027 growing at a compound annual growth rate (CAGR) of 9.3%, the company appears well positioned for continued growth. This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

February 16, 2023 09:15 AM Eastern Standard Time

Healixa Inc and WATERisLIFE Collaborate to Address the Global Water Scarcity Crisis with Global AquaDuct® Deposition Water Harvesting™ Technology

Healixa Inc.

McapmediaWire -- Healixa, Inc. (OTC: EMOR ) (“Healixa,” or the “Company”), a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water, and green-tech industries and WATERisLIFE, a global non-profit organization working to end the world water crisis, today announced their collaboration. The two organizations agreed to work together to respond to the growing water scarcity challenges in North America and internationally following recently completed demonstration of Healixa's proprietary Global AquaDuct® Deposition Water Harvesting™ Technology ("DWH ™ ") for multiple current and former US government officials and humanitarian experts. Healixa's DWH ™ technology is the world's first and only water vapor harvesting technology that can produce potable water directly from the earth's atmosphere by leveraging multiple proprietary advancements including phase-change, thermal deposition, and drawing operating power from on-grid or off-grid (solar) sources. Global AquaDuct® is a revolutionary approach to atmospheric water harvesting, providing a turnkey, sustainable, primary source of potable water in a compact form factor (only 12 sq. ft.), capable of directly addressing the significant limitations of competing technologies, to deliver substantially improved operational performance including energy efficiency, no relative humidity dependency, and constant reliable yield. Ken Surritte, Chairman, and founder of WATERisLIFE, said "Access to clean water is quickly becoming one of the most critical global challenges facing mankind. Water scarcity and droughts knows no borders and is increasingly threatening farmlands and communities in the developed world, just as it has in historically water-challenged geographies such as in Africa and the Middle East. Having seen first-hand the capabilities of Healixa's Global AquaDuct® technology, we believe this impressive and innovative solution has the potential to radically improve the lives of millions of people around the world. That is why are so excited to work with the Healixa team to showcase the impact that Global AquaDuct® can have in assisting communities around the global address their water insecurity challenges." "Healixa is dedicated to the development and commercialization of technologies that can positively impact the lives of millions. Having recently completed early-stage commercialization and testing of our Global AquaDuct® water harvesting technology, we are confident in its unmatched capabilities and potential. We are pleased to work alongside leading humanitarian organizations such as WATERisLIFE as we expand the awareness of our unique DWH ™ technology and advance our commercialization efforts with potential customers," added Ian Parker, Chairman and CEO of Healixa. About Healixa, Inc. Healixa is a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water generation and green-tech industries. Healixa embraces innovation by combining its intellectual properties, patents, strategic collaborations, and partnerships to create a "LaunchPad" of disruptive sustainable products. For more information, visit www.healixa.com. About WATERisLIFE WATERisLIFE is a 501 (c)(3) public charity bringing life-changing water solutions to the areas of the world that need it the most. For nearly two decades, WATERisLIFE has been working with the UN and the sustainability goals established by the UN for bringing safe water around the world. We aim to solve the world water crisis through better WASH (water, sanitation, and hygiene) programs in developing countries. WATERisLIFE brings cutting-edge technologies to the 47 countries we have been doing projects in. WATERisLIFE water, sanitation, and hygiene solutions have reached more than 60,000,000 people worldwide since inception. For more information, visit the website at www.WATERisLIFE.com Safe Harbor Statement Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Healixia Contact: Bret Hedges SVP of Strategic Partnerships 833-432-5492 Bret@healixa.com WATERisLIFE Contact: Director of Communications Cote@WATERisLIFE.com Contact Details Healixia Bret Hedges +1 833-432-5492 Bret@healixa.com WATERisLIFE Director of Communications Cote@WATERisLIFE.com

February 16, 2023 08:52 AM Eastern Standard Time

Faron Pharmaceuticals CMO "looking forward to a year filled with good data for the patients"

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief medical officer Marie-Louise Fjällskog updates Proactive's Thomas Warner the clinical-stage biopharmaceutical company's wholly-owned precision immunotherapy asset, Bexmarilimab. Fjällskog says that she's "looking forward to a year filled with good data for the patients." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 16, 2023 07:10 AM Eastern Standard Time

Video

Arecor Therapeutics "confident" in collaboration pipeline after another new deal

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Proactive's Thomas Warner after announcing the biopharma group has signed another collaboration deal with a top five pharmaceutical partner. The deal is the eighth of its type since the group’s listing in May 2021 and Howell says that she’s “confident” that the company will be announcing more such collaborations in the coming months. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 16, 2023 05:55 AM Eastern Standard Time

Video

News Release

BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Proactive's Steve Darling to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s red grape cell (RGC) composition to promote eye health. RGC is produced using BioHarvest's Botanical-Synthesis technology. Sobel told Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis-related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 15, 2023 01:21 PM Eastern Standard Time

Video

Start the New Year with Cellular Energy Support

YourUpdateTV

For many, the holidays proved difficult for sticking to healthy routines. And it can be even harder to be motivated to prioritize your overall wellness throughout the year. But incorporating a healthy diet, exercise and supplements into your routine may help you work towards sticking to your New Year wellness goals. When your metabolism works optimally, it does a great job of supporting overall wellness. Recently, Dr. Nicole Avena, consultant for Jarrow Formulas, conducted a satellite media tour to share insights on how to support cellular energy production and gave tips on how to evaluate your daily nutrition and balance your diets with supplements such as vitamin B12. A video accompanying this announcement is available at: https://youtu.be/f7VxR7tOVSQ Ideally, we would all absorb optimal amounts of nutrients through a well-balanced diet – but this can be difficult to achieve. To support immune health, it’s important to evaluate daily nutrition and balance our diets with efficacious, scientifically based supplements. The Methyl B-12 from Jarrow Formulas, for example, is naturally recognized by your body, so it is delivered to your cells more effectively than a non-methyl B12 – all to support energy production at the cellular level.* Even more, Jarrow Formula’s Methyl B-12 is the perfect complement to a plant-based diet as it provides the same form of B12 found in animal-based food, and in a vegan chewable tablet. Methyl B-12 is a water-soluble vitamin and is the metabolically active and bioavailable form of vitamin B12 that helps support brain and nerve health, cellular energy production and sleep.* Together with folic acid, it also helps to reduce homocysteine levels to support good health.* Jarrow Formulas Methyl B12 is a vitamin supplement especially useful for vegetarians and people over 50 to help support adequate vitamin B12 levels. However, adequate Methyl B-12 status over the whole lifecycle is needed for optimal health. The suggested usage of our Methyl B-12 is to dissolve in mouth or chew 1 tablet per day or as directed by your qualified healthcare professional. Risk Factors for Vitamin B12 Deficiency Advancing age and diet are the primary risk factors for low vitamin B12 levels. It is recommended that people over 50 consider supplements and vitamin B12-fortified foods. Indeed, up to 40 percent of older individuals may have reduced stomach acid, which impairs absorption of vitamin B12.* Diet is a major risk factor for inadequate vitamin B12 levels. The best sources of vitamin B12 are animal products, such as meat, eggs, and fish. Therefore, strict vegetarians (those who eat no animal products) are at considerable risk. Jarrow Formulas has been carefully crafting vitamins, minerals and supplements since 1977. Informed by strong scientific research, Jarrow Formulas’ products have the potential to support and promote optimal health. For more information, visit Jarrow.com - *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. About Dr. Nicole Avena Dr. Nicole Avena is a research neuroscientist and a pioneer in the field of food addiction. Her seminal research work jump-started a new field of exploration in medicine and nutrition. She is an expert in diet during pregnancy and baby, toddler and childhood nutrition. Dr. Avena received a Ph.D. in Neuroscience and Psychology from Princeton University, followed by a postdoctoral fellowship in molecular biology at The Rockefeller University in New York City. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 15, 2023 12:20 PM Eastern Standard Time

Video

With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO

Sharps Technology Inc.

By David Willey, Benzinga Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in manufacturing and marketing, and is rolling out the first of its innovative syringe products. The syringe market is worth over $6 billion. The pandemic raised public awareness about the importance of a strong and steady syringe supply. Now, pharmaceutical and manufacturing companies are turning to next-generation solutions like prefillable syringes, which deliver medicine utilizing enhanced features and benefits that will support a lower cost of total ownership (TCO) for healthcare companies. Sharps Technology is a medical device and drug delivery company focusing on specialized and prefillable syringes. Public since April 2022, Sharps is looking to fulfill demand in the market and modernize syringe offerings through its line of polymer prefillable and ultra-low waste safety syringes. A year on from its IPO, Sharps can reflect on a series of robust company successes and exciting developments. IPO, Manufacturing Successes, And A Key Partnership IPO. Sharps launched its IPO of common stock in April 2022. The company issued 3.75 million units of public stock at $4.25 per unit, with proceeds from the IPO coming to around $16 million. Hungary Facility. The company acquired a manufacturing facility in Hungary, which allows Sharps to manufacture its smart safety syringes with a production capacity of 50 million units. It shipped its first set of containers of smart safety syringes early this year, bringing them from its Hungarian facility to U.S. partner, Nephron Pharmaceuticals headquartered in South Carolina. Sharps CEO, Robert Hayes, commented on the shipment, “With the first shipments of Securegard underway to Nephron, we mark the beginning of commercial operations for Sharps. We are committed to executing on our manufacturing and distribution plan, and through this shipment the Company will transition to revenue in the first half of 2023.” Nephron Collaboration. Sharps entered a major partnership with leading drug and manufacturing services company Nephron Pharmaceuticals Corporation. The collaboration will allow Sharps access to manufacturing and marketing solutions at Nephron, and will include full access to Nephron's analytical labs for continued product development. The partnership allows Sharps to accelerate the development and manufacturing of its product line of prefillable syringe systems. Robert Hayes, Sharps Chief Executive Officer, recently stated: “Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opportunity to advance our product and manufacturing strategy to include high-value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the U.S. that provide specialized solutions for customers that need options for their drug-filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market.” Other companies working in the syringe market are Becton Dickson and Co. (NYSE: BDX), Cardinal Health (NYSE: CAH), Novo Nordisk N/S (NYSE: NVO), and Terumo Corporation (OTC: TRUMY). This article was originally published on Benzinga here. Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Adam Holdsworth- TraDigital IR adam@tradigitalir.com Company Website http://sharpstechnology.com/

February 15, 2023 09:55 AM Eastern Standard Time

How To Improve Mental Well-Being — TruBrain’s Non-Pharmaceutical Solutions Could Help Fight Anxiety For Stress-Free Living

TruBrain

By David Willey, Benzinga You can invest in TruBrain and be a part of their growth story! Click here to learn more. Stress is so ubiquitous today that it has been called “a national mental health crisis.” Being bombarded with rising food prices, novel virus variants, layoffs and inflation means it's important to get your mind right and your anxiety managed so you can have a successful 2023. The Los Angeles-based cognitive health company TruBrain might have the solution you need for achieving that calm and anxiety-free mind. Anxiety is overwhelming for Millenials and Gen Z, with over 50% of those under 35 reporting dealing with crippling stress levels daily. The US represents the largest segment of the global anxiety and depression market, and with the worrying risks of side effects and addiction associated with anxiety medication like benzodiazepine, there’s growing interest in a non-pharmaceutical solution to stress. TruBrain is a natural cognitive enhancing nutrition company, with a variety of products that promote clarity of thought, sharp memory, and peaceful sleep. The company is riding the wave of a $3.3 billion nootropic market growing in popularity by developing drinks and other products which promote clear and calm concentration, and it’s excited to help people maximize their brain potential for healthier living. TruBrain’s Products For Mental Well-Being Set to be a leader of nootropic drinks and with 5 stars from over 571 reviews, TruBrain’s most popular product is its personalized drinks package, whose extensive range means each person can personalize their drinks to treat their brain best. Its science-backed drinkable products include key nootropics and minerals to reduce stress and unlock focus. The drinks, which were developed by a team of University of California Los Angeles-trained (UCLA) neuroscientists, have been shown by EEG brainwave analyses and third party clinicals studies to promote healthy brain functions like improved memory, verbal fluency, and alpha brain activity. TruBrain was also recently rated the best nootropics for dealing with stress and anxiety. The cognitive healthcare company is also excited about its upcoming wearable tech which tackles anxiety by supporting natural brain activity. TruBrain’s Smart Wearable uses Food and Drug Administration (FDA)-cleared tech to send safe, micro electric currents to increase blood flow to key parts of the brain, giving users a non-pharmaceutical solution to lessen anxiety and promote calm. Backed by thousands of scientific studies and decades of research, the tech used by TruBrain provides neurostimulation that can produce results in just 30 minutes, activating neurons and nudging neurotransmitter activity for a clear and stress-free mind. “Our mission is to empower people to do their best thinking,” said CEO of TruBrain Chris Thompson. “The problems we’re trying to solve are stress and anxiety. That will clear the runway for you to focus more, relax and get better sleep.” TruBrain has made over $19 million in lifetime sales and has been profitable since 2019. Supported by 2000+ grassroots investors and with over $4 million already raised, the company has built a robust distribution network with the mission to become the leading cognitive healthcare brand. TruBrain’s comparables in the space are successful companies like Hims (NYSE: HIMS), RXBar, Amplify Snack Brands, and others. TruBrain is currently raising funds via a new round of investing, with investors getting free products to sample – will it become the next healthcare success story? Want to find out how to invest in TruBrain? Click here. Want to learn more about TruBrain? Visit its website here. This article was originally published on Benzinga here. TruBrain is a profitable brand in high-performance cognitive nutrition with over $18 million in lifetime sales. We deliver patent-pending brain food designed by neuroscientists to enhance your memory, focus, sleep, and more. Our personalized formulas will empower you to be the best version of your unique self. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details TruBrain Investor Relations invest@trubrainstock.com Company Website https://www.trubrain.com/

February 15, 2023 09:25 AM Eastern Standard Time

Applied UV’s (NASDAQ: AUVI) Subsidiary Embarks On Research Partnership With Johnson Controls And Ushio America To Study The Efficacy And Safety Of Filtered Far UV-C Disinfection Technology

Applied UV, Inc.

By Ernest Dela Aglanu, Benzinga Applied UV Inc. (NASDAQ: AUVI) is leading a new wave of innovation in the ultraviolet (UV) disinfection equipment industry. This is good, considering the critical role UV plays in keeping indoor spaces and medical facilities free of pathogens. UV disinfection has been a proven technology for the disinfection of pathogens on surfaces and in air and water for several decades. A particular spectrum of UV radiation between 200 and 280 nm – the UVC spectrum – has been employed extensively as the germicidal range of UV radiation. Global health crises, like the COVID-19 pandemic, highlight the scientific and engineering potential of applying UV disinfection technologies for biocontaminated air and surfaces as the major media for disease transmission. More businesses and institutions, such as healthcare facilities, shopping malls and airports, are increasingly adopting UV devices for disinfecting frequently touched surfaces and circulating air streams. The increasing adoption of UV disinfection is translating into a positive growth outlook for the market, something investors are always looking out for. Grand View Research projects the global disinfection equipment market will reach $6.17 billion by 2030, expanding at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. So, for a player like Applied UV, which develops and acquires proprietary infection prevention and control technology in the healthcare, commercial and public venue, food processing and storage, cannabis, and education markets, the advancing growth of the market presents opportunities. The company has two wholly owned subsidiaries — SteriLumen Inc. and Munn Works LLC. SteriLumen owns and markets a portfolio of products with advanced pathogen elimination technology, branded Airocide® by SteriLumen, Scientific Air™ by SteriLumen, Airoclean™ 420 by SteriLumen, and Lumicide™ by SteriLumen. Research Collaboration To Study The Efficacy And Safety Of Far-UVC Disinfection Technology In a quest to advance and enhance its technology, Applied UV recently announced that its subsidiary, PURO Lighting LLC, a proven innovative UV technology solutions leader, Johnson Controls International PLC. (NYSE: JCI), a leader for smart, healthy, and sustainable buildings, and Ushio America Inc., have announced a research collaboration to study the efficacy and safety of far-UVC disinfection technology. Far-UVC is a narrow band of UVC light centered at 222nm, which is proven to inactivate pathogens at levels that are safe for human exposure and can be used in spaces where people are present. While the efficacy of filtered far UV-C light disinfection is widely known, there is limited research on the ancillary effects that occur from the inactivation of pathogens using far UV-C light. Therefore, the planned study being embarked upon by PURO and Ushio will allow for a better understanding of the possible positive and negative impact the elimination of pathogens has on the surrounding air. “The further validation of the safety and efficacy of filtered far UV-C technology presents tremendous opportunity for PURO to accelerate market adoption by sponsoring this critical research,” Brian Stern, president of PURO, said in a press release. He further noted that the research will help demonstrate the benefits and potential cost savings that continuous disinfection of air and surfaces can bring to workplace settings, including hospitals, schools, government buildings, commercial offices and other shared indoor spaces. Tyler Smith, vice president of Healthy Buildings, Johnson Controls, on his part explained that “Better indoor air quality (IAQ) is increasingly important to our customers and our employees, and it’s critical we evaluate all of the factors that go into the IAQ equation.” “We are intrigued and excited by the early promise of far UV-C as a supplement to our leading IAQ solution portfolio. By testing PURO and Ushio’s market-leading far UV-C technologies, we will be able to provide customers with additional, proven, safe and effective solutions to ensure that the air and surfaces in indoor spaces are healthier and more sustainable,” he added. For Ushio, the research collaboration presents an opportunity for the company to build on its existing research and findings to further prove the efficacy and safety of Care222 filtered far UV-C technology. “The capability to provide continuous UV disinfection of air and surfaces in occupied spaces has become the industry standard. This research will help provide the confidence to customers that the technology is not only effective but safe,” Shinji Kameda, COO of Ushio, said. The research agreement, which includes technologies and products from PURO and Ushio, will focus on testing regulatory-approved filtered far UV-C lighting technologies. The research will be conducted by leading U.S.-based universities and certified laboratories over the next six to eight months. The findings from the results will be provided as they become available. A recently released white paper from Johnson Controls highlights that better indoor air quality can conservatively lead to a $750 to $800 return per employee per year by reducing absenteeism from health issues and the reduction in productivity due to poor air quality. This article was originally published on Benzinga here. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

February 15, 2023 09:00 AM Eastern Standard Time

1 ... 132 133 134 135 136 ... 248